News articles about Viking Therapeutics (NASDAQ:VKTX) have been trending somewhat positive this week, according to Accern Sentiment. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Viking Therapeutics earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 45.5499167396579 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
VKTX has been the subject of a number of research reports. ValuEngine downgraded Viking Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, July 28th. HC Wainwright reissued a “buy” rating and set a $7.00 price target (up previously from $5.00) on shares of Viking Therapeutics in a research report on Monday, July 17th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $5.00 target price on shares of Viking Therapeutics in a research report on Thursday, May 11th.
Shares of Viking Therapeutics (NASDAQ VKTX) traded up 1.00% during midday trading on Friday, hitting $1.01. The stock had a trading volume of 47,217 shares. The firm has a 50-day moving average price of $1.06 and a 200-day moving average price of $1.26. Viking Therapeutics has a 1-year low of $0.88 and a 1-year high of $1.70. The firm’s market cap is $27.97 million.
Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by $0.02. On average, equities analysts anticipate that Viking Therapeutics will post ($0.82) EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Viking Therapeutics (NASDAQ:VKTX) Receives Daily News Impact Rating of 0.23” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.com-unik.info/2017/08/19/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-viking-therapeutics-nasdaqvktx-share-price-updated.html.
About Viking Therapeutics
Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.
What are top analysts saying about Viking Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Viking Therapeutics Inc. and related companies.